GGrantIndex
← Leaderboards

Richard K Burt

Northwestern University

$3,156,179
Attributed
$3,156,179
Total exposure
16
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $338.5K · FY200507
$500K$375K$250K$125K$0
'05
'06
'07

Funding mix

By agency

NIH$3,156,179 · 16

By mechanism

N01$2,413,890 · 1
M01$742,289 · 15

Top collaborators

No co-investigators on record.

Most similar at Northwestern University

Same institution · by research overlap

Others in their field

Top investigators on “Human Therapy Evaluation

Research focus

Human Therapy EvaluationClinical ResearchHuman SubjectBone Marrow TransplantationHematopoietic Stem CellsImmune Tolerance /UnresponsivenessCyclophosphamideT LymphocyteArtificial ImmunosuppressionAutologous TransplantationNeoplasm /Cancer Remission /RegressionMultiple SclerosisImmunopathology ChemotherapyImmunoglobulinsImmunopathology TherapyImmunosuppressionPatient Oriented ResearchCombination TherapyPassive ImmunizationGanciclovirGene TherapyGenetic TransductionGraft Versus Host DiseaseHomologous Transplantation

Grant awards (20)

PHASE I HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PERIPHERAL VASCULAR DISEASE$21,935
M01 · FY2007 · RR · contact PI
MSAUTO 2002 HEMATOPOIETIC STEM CELL THERAPY FOR PATIENTS WITH MS$20,564
M01 · FY2007 · RR · contact PI
PHASE II HEMATOPOIETIC STEM CELL SUPPORT IN PATIENTS WITH SYSTEMIC SCLERODERMA$4,113
M01 · FY2007 · RR · contact PI
MSAUTO 2002 HEMATOPOIETIC STEM CELL THERAPY FOR PATIENTS WITH MS$25,341
M01 · FY2006 · RR · contact PI
HSCT IN PERIPHERAL VASCULAR DISEASE: A PHASE I STUDY$21,118
M01 · FY2006 · RR · contact PI
CYCLOPHOSPHAMIDE & CAMPATH WITH HSC IN PATIENTS WITH SCLERODERMA$19,006
M01 · FY2006 · RR · contact PI
MSAUTO 2002 HEMATOPOIETIC STEM CELL THERAPY FOR PATIENTS WITH MS$247,278
M01 · FY2005 · RR
DIAD SCLAUTO2001: HEMATOPOIETIC STEM CELL IN PATIENTS WITH SCLERODERMA$42,825
M01 · FY2005 · RR
MGAUTO2002 HEMATOPOIETIC STEM CELL THERAPY FOR PATIENTS WITH MYASTHENIA GRAVIS$38,680
M01 · FY2005 · RR
DIAD VASCULITIS-AUTO2002: HEMATOPOIETIC STEM CELL THERAPY FOR VASCULITIS$9,670
M01 · FY2005 · RR
MS.Auto 2002 Hematopoietic Stem Cell Therapy for Patients with MS$165,921
M01 · FY2004 · RR
DIAD Vasculitis-Auto2002: Hematopoietic Stem Cell Therapy for Vasculitis$35,136
M01 · FY2004 · RR
DIAD Scl.Auto2001: Hematopoietic Stem Cell in Patients with Scleroderma$29,280
M01 · FY2004 · RR
DONOR LYMPHOCYTES TRANSDUCED WITH HERPES SIMPLEX THYMIDINE KINASE GENE$0
M01 · FY2001 · RR
IMMUNE ABLATION AND HEMATOPOIETIC STEM CELL SUPPORT IN PATIENTS WITH SLE$0
M01 · FY2001 · RR
IMMUNE ABLATION/HEMATOPOIETIC STEM CELL SUPPORT IN PATIENTS WITH MALIGNANT MS$0
M01 · FY2001 · RR
STEM CELL TRANSPLANTATION FOR TX OF AUTOIMMUNE DISEASES$2,413,890
N01 · FY2000 · AI
IMMUNE ABLATION AND HEMATOPOIETIC STEM CELL SUPPORT IN PATIENTS WITH SLE$20,474
M01 · FY2000 · RR
DONOR LYMPHOCYTES TRANSDUCED WITH HERPES SIMPLEX THYMIDINE KINASE GENE$20,474
M01 · FY2000 · RR
IMMUNE ABLATION/HEMATOPOIETIC STEM CELL SUPPORT IN PATIENTS WITH MALIGNANT MS$20,474
M01 · FY2000 · RR